Dr. Bora Sieng, from Arctic Pharma, advocates for the importance of chemistry and encourages pupils to pursue a career in the exciting field of chemistry.
Author Archive for: oslocancer
This author has yet to write their bio.Meanwhile lets just say that we are proud oslocancer contributed a whooping 146 entries.
Entries by oslocancer
What kind of work does it take to receive PERMIDES funding for innovative concepts and projects?
Learn how Project DoMore! aims to better cancer treatment through modernized thinking and technological solutions.
The Department of Cellular Therapy is great at transforming cancer research into new companies.
24 oncology innovators from 9 international hubs attended the 6th International Cancer Cluster Showcase in San Diego.
Oslo Cancer Cluster aims to enhance the visibility of oncology innovation made in Norway. Find out how we go about making this happen.
Meet our newest board members!
Doctors, researchers and audience gather at breakfast to learn about genetics, data and how working together will help beat cancer.
A driving force behind the collaboration between Ullern Upper Secondary School and Oslo Cancer Cluster is stepping down. This is her adventure.
The cluster-to-cluster project PERMIDES stimulates collaboration between biotech companies and IT companies. Join the workshop in Oslo 24 May.
Oslo Cancer Cluster Incubator stakk av med Siva-prisen for 2017 på årets Siva-konferanse i Trondheim.
Thermo Fisher Scientific is one of three finalists to win the award and title in Oslo this Tuesday. The technology which the biotech company is nominated for, is development of faster and cheaper DNA-sequencing. More than 70 companies were candidates for this year’s price, according to the Norwegian online tech magazine Teknisk Ukeblad. Thermo Fisher Scientific is one […]
En ny rapport om helsenæringens verdi er ute. Du kan laste ned rapporten her.
Oslo Cancer Cluster member Roche has received approval by the Norwegian Medicines Agency for a medication against a specific form for lung cancer.
Join six pupils from Ullern Upper Secondary School to see how physics plays a crucial role in good cancer treatment.
The bioinformatics company OncoImmunity AS was ranked fourth out of 250 applicants for this prestigious grant.
Oslo Cancer Cluster member Vaccibody is moving forward with the first vaccination of a patient with the HPV-virus in a IIa study using the company´s immunotherapy.
Why join the PERMIDES platform? It is where you can find your biopharma-IT match.
Åtte elever fra Ullern videregående skole har denne uken vært på utplassering hos avdeling for patologi ved Oslo universitetssykehus. Morsomt har det vært, og Marie Wahlstrøm kan godt tenke seg å bli patolog.
Targovax ASA’s shares have been accepted to list on Oslo Børs, the main Oslo Stock Exchange. Targovax is a clinical stage company, developing immuno-oncology therapies to target treatment-resistant solid tumors.
The first call for proposals for the PERMIDES project is opening on March 15th. We urge all small and medium sized biopharma-companies working to take the step into the digital era: Apply for funding up to 60 000 Euros.
Nordic Mentor Network for Entrepreneurship (NOME) is an elite Nordic mentoring program for promising life science projects and startups with world class mentors.
Oslo Cancer Cluster member BerGenBio enters collaboration with MSD focused on clinical evaluation of BGB324 in combination with KEYTRUDA® (pembrolizumab) in advanced lung and breast cancer.
We are currently looking for an EU advisor with skills and experience in writing EU funding proposals. This is a fixed term contract with duration to the end of 2018.
IRW Consulting, Eisai and Personalis, Inc. are all new members of the Oslo Cancer Cluster. Please read more about them here.
De nordiske landene bør samarbeide mer for å utvikle bedre kreftbehandlinger. Sammen kan Norden bli et globalt forsknings- og testsenter for nye kreftbehandlinger og -medisiner. Det kan gi store gevinster for kreftpasienter i hele verden. Denne kronikken sto på trykk i Aftenposten torsdag 9. mars. Ketil Widerberg, daglig leder i Oslo Cancer Cluster, skrev kronikken samme uke som The Economist, Forskningsrådet og […]
Oslo, Norway, 6 March 2017: Targovax ASA (“Targovax” or “the Company”; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target, primarily, treatment-resistant solid tumors, announces that members of its senior management will present at the following life sciences and investor conferences:
– 10th European Life Science CEO Forum
– Redeye – Fight Cancer Seminar
– 11th Annual BIO-Equity Spring 2017 Conference
Oslo Cancer Cluster has a new Head of Communications. She wants to help you reach out.
Oslo Cancer Cluster member Radium Hospital Research Foundation, Radforsk, has launched their own podcast. The podcast is named Radium, and is about cancer research and development of new cancer treatments, as well as updates on Radforsk´s portfolio companies.
Oslo, Norway, 16 February 2017 – Targovax ASA (“Targovax” or “the Company”; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces its fourth quarter and full year 2016 results.
A meeting for investors, analysts and press will take place in Oslo today at 10:00 CET and a conference call will take place at 14.00 CET (details below).
Are you a startup or entrepreneur in Healthcare or Life-Sciences? If yes – keep reading!
Oslo Cancer Cluster member Photocure ASA reported that full year 2016 revenues ended at NOK 143.6 million (134.7). Photocure targets revenues from the US operations to quadruple to a range of USD 15 million by 2020.
Cancer Crosslinks is now one of the most relevant meetings for Norwegian oncologists, with 300 delegates attending this year. You may download the presentations here.
Oslo Cancer Cluster is proud to be partner of the Economist Events War On Cancer Nordics. The event will gather leaders in oncology from the Nordic region and beyond, to discuss the region’s primary challenges in cancer care and control.
Our portfolio company Oncoinvent announced today the closing of a 210 MNOK (approx. 25 MUSD) private placement of ordinary shares. Financing will support development of Radspherin™, a novel radiotherapeutic treatment for peritoneal carcinomatosis.
The Norwegian Research Council recently granted funding to Oslo Cancer Cluster members; BerGen Bio, Bionor Immuno, GE Healthcare, Lytix Biopharma, PCI Biotech and Phoenix Solutions.
Oslo Cancer Cluster member Targovax will announce its fourth quarter and full year 2016 results on Thursday, 16 February 2017.
Lytix Biopharma, a clinical-stage biopharmaceutical company developing novel cancer immune therapies, has been awarded a NOK 15.9 million grant from The Norwegian Research Council (User-driven Research-based Innovation) to support the investigation of LTX-315’s ability to make ’’cold tumors hot’’ and Phase II trial in Triple Negative Breast cancer (TNBC).
Survival rate of 68% from first patient cohort vs published historical rate of 30-53% suggests signal of clinical efficacy for the drug candidate. Full data set from first patient cohort to be submitted for presentation at ASCO annual meeting in June.
Oslo Cancer Cluster member Lytix Biopharma has been awarded a NOK 15.9 million grant from The Norwegian Research Council.
Our member PCI Biotech has been granted NOK 13.8 million to the project “Photochemical vaccination – novel immunotherapy concept for treatment of cancer and infectious diseases”.
Cancer Crosslinks 2017 on January 26 features a really interesting program with International and Norwegian thought leaders presenting recent findings within cancer research.
PCI Biotech, Ultimovacs, Arctic Pharma, Oncoimmunity and Myhere have been granted funding to develop improved cancer treatments through collaborative projects.
Dehns Patent and Trade Mark Attorneys recently joined the Oslo Cancer Cluster. Dehns is one of Europe’s largest firms of patent and trade mark attorneys and has a 40 year history of working with Norwegian organisations such as: Dynal, Inven2,Lytix Biopharma, Nextera, NMBU, NTNU, Nycomed, PCI Biotech and Photocure. As members, our aim is to […]
The PCI Biotech and Ultimovacs collaboration awarded NOK 500,000 from Innovation Norway
Oslo Cancer Cluster Innovation Park´s grand opening on August 24th became a very special day: More than 290 invited guests and a huge media turnout celebrated the initiators Jónas Einarsson and Kaare Norum for turning the radical idea of an oncology innovation park integrating a high school into reality.
Contact us >
Oslo Cancer Cluster is an oncology research and industry cluster dedicated to improving the lives of cancer patients by accelerating the development of new cancer diagnostics and medicines.
We are a national non-profit member organization with about 90 members. Our members are Norwegian and international companies, research and financial institutions, university hospitals and organizations – all working in the cancer field.